Status
Conditions
About
This study will examine the clinical, immunological and epidemiological effects of concurrent infections with P. falciparum and W. bancrofti or M. perstans (the parasites that cause malaria and filariasis) on the frequency and severity of malaria infection in children and young adults in Mali, Africa.
Residents of Tien gu bougou and Bougoudiana, Mali, who are between 1 and 20 years of age may be eligible for this study. Participants with and without filarial infection will be enrolled.
Participants undergo the following tests and procedures:
Full description
Residents of malaria-endemic regions are frequently exposed to a variety of other parasites concurrently with malarial parasites. In Mali, lymphatic filariasis due to Wuchereria bancrofti co-exists in several regions highly endemic for malaria, and co-infection is common in the residents of these areas. Because of the chronicity of filarial infections and an associated bias towards the development of an adaptive immune response dominated by Th2 cytokines, a pre-existing filarial infection has the potential to alter the immune response towards incoming malarial parasites, clearance of which are considered to be dependent on a robust Th1 response. This could, in turn, affect the clinical manifestations and outcomes of malaria infection. Conversely, immune responses to filarial parasites may be modulated in the presence of malarial parasites. In addition to sharing a human host, Plasmodium falciparum and Wuchereria bancrofti are transmitted by the same mosquito vector, Anopheles gambiae, and interaction between the two species in the vector may have important implications for transmission of these two infections. The primary goals of this study are to determine the effect of concurrent infections with P. falciparum and W. bancrofti parasites on the prevalence and severity of malaria infection in children living in a Malian village co-endemic for two parasites and to assess the effects of co-infection on the immune responses to these two parasites over the course of the malaria transmission season. The epidemiology of co-infection at the human and vector level will also be examined.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Age 1 - 20 years
Male or non-pregnant female
Resident of Tien gu bougou or Bougoudiana
EXCLUSION CRITERIA (Screening):
History or clinical evidence of severe and/or chronic illness
History of allergy to artesunate, amodiaquine, albendazole, praziquantel or mebendazole
Plans to relocate outside the immediate vicinity of the village during the study period
INCLUSION CRITERIA (Matched prospective study):
Age 1 - 20 years
Male or non-pregnant female
Resident of Tien gu bougou or Bougoudiana
EXCLUSION CRITERIA (Matched prospective study):
History or clinical evidence of severe and/or chronic illness
History of allergy to artesunate, amodiaquine, albendazole, praziquantel or mebendazole
Plans to relocate outside the immediate vicinity of the village during the study period
Hemoglobin less than or equal to 8 g/dL
Symptoms of malaria with parasitemia greater than or equal to 100,000/microliters at enrollment
Recent history or clinical evidence of prostration, bleeding, respiratory distress, seizures, coma or obtundation, jaundice, inability to drink, persistent vomiting
INCLUSION CRITERIA: (Immunologic Extension Study)
Age > 10 years
Male or non-pregnant female (by history)
Resident of Tien gu bougou or Bougoudiana
Willingness to allow storage of specimens for future research
EXCLUSION CRITERIA: (Immunologic Extension Study)
History or clinical evidence of severe and/or chronic illness
Hemoglobin less than or equal to g/dL
Positive pregnancy test
Clinical malaria (symptoms of malaria plus any malaria parasites identified on thick smear)
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal